Data from the late-stage trial of amlitelimab weren’t as strong as the results seen in Phase 2, adding to doubts about a drug ...

World Atopic Eczema Day 2025 highlights the lifelong impact of atopic eczema, a common inflammatory skin disease that often ...

Sanofi (NASDAQ:SNY) stock took a beating Thursday after its latest eczema drug trial left Wall Street unconvinced, even ...

Eczema can be managed with certain self-care regimens, such as fragrance-free soap, brief lukewarm baths or showers, and regular skin hydration with a strong emollient like CeraVe cream or Vaseline.

World Atopic Eczema Day 2025 calls for early intervention, better care and greater awareness of the hidden toll of atopic ...

Sanofi (SNY) stock drops after Phase 3 trial results for amlitelimab, its experimental therapy for eczema, disappointed ...

Eczema, or atopic dermatitis, often worsens during seasonal changes like monsoon and autumn. Fluctuating humidity, allergens, ...

Sanofi stated that these positive results strengthen amlitelimab's potential as a treatment for atopic dermatitis. The company is currently conducting additional late-stage trials of the drug, which ...

Dupixent, which Sanofi jointly developed and co-owns with drugmaker Regeneron, is approved not only for eczema but also for ...

Besides mosquito bites, other causes of itchy bumps on your skin may include hives, other bug bites like flea bites, and ...